New research article in The Lancet Infectious Diseases>

Safety and immunogenicity of a ChAdOx1 #vaccine against #RiftValleyFever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00068-3/fulltext

#RVF

New @LancetGH viewpoint>

#Aedes albopictus invasion across Africa: the time is now for cross-country collaboration and control

https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(23)00046-3/fulltext

#Arbovirus #dengue #chikungunya #RiftValleyFever